

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com



6042 Cornerstone Court West, Suite B San Diego, CA 92121 **Tel:** 1.858.202.1401

Tel: 1.858.202.1401 **Fax:** 1.858.481.8694

Email: info@bpsbioscience.com

Data Sheet

Hippo Pathway TEAD Reporter – MCF7 Cell Line Catalog #: 60618

Background

The Hippo pathway regulates cell proliferation and cell death. It is activated by high cell density and cellular stress to stop cell proliferation and induce apoptosis. The mammalian Hippo pathway comprises of the MST and LATS kinases. When the Hippo pathway is activated, MST kinases phosphorylate the LATS kinases, which phosphorylate the transcriptional co-activators YAP and TAZ. Dephosphorylated YAP and TAZ remain in the nucleus and interact with the TEAD transcriptional factors to induce cell cycle-promoting gene transcription. However, when phosphorylated, YAP and TAZ are sequestered in the cytosol, and YAP and TAZ-dependent gene transcription is turned off. Dysfunction of the Hippo pathway is frequently detected in human cancer and its down-regulation correlates with the aggressive properties of cancer cells and poor prognosis.

Description

The TEAD Reporter – MCF7 cell line contains the firefly luciferase gene under the control of TEAD responsive elements stably integrated into the human breast cancer cell line MCF7. Inside the cells, basal dephosphorylated YAP and TAZ remain in the nucleus and induce constitutive expression of the luciferase reporter. The cell line is validated for the inhibition of the expression of the luciferase reporter by the activators of the Hippo pathway, as well as activation of the luciferase reporter by inhibitors of the Hippo pathway.

Application

- Monitor Hippo pathway activity.
- Screen for activators or inhibitors of the Hippo pathway.

Format

Each vial contains ~1.5 X 10⁶ cells in 1 ml of 10% DMSO.

Storage

Store in liquid nitrogen immediately upon receipt.

General Culture Conditions

Thaw Medium 1 (BPS Bioscience #60187) + 10 μg/ml of Insulin (Sigma-Aldrich #10516): MEM medium (Hyclone #SH30024.01) supplemented with 10% FBS (Invitrogen #26140-079), 1% non-essential amino acids (Hyclone #SH30238.01), 1 mM Na pyruvate (Hyclone #SH30239.01), 1% Penicillin/Streptomycin (Hyclone SV30010.01), plus 10 μg/ml of insulin (Sigma-Aldrich # I0516).



Tel: 1.858.202.1401 **Fax:** 1.858.481.8694

Email: info@bpsbioscience.com

Growth Medium 1B (BPS Bioscience #79531) + 10 μ g/ml of Insulin (Sigma-Aldrich #10516): Thaw Medium 1 (BPS Cat. #60187) + 10 μ g/ml of insulin (Sigma-Aldrich #10516), and 400 μ g/ml of Geneticin (Invitrogen #11811031).

Cells should be grown at 37° C with 5% CO₂ using Growth Medium 1B with 10 µg/ml of Insulin. It may be necessary to adjust the percentage of CO₂ in the incubator depending on the NaHCO₃ level in the basal medium.

To thaw the cells, it is recommended to quickly thaw the frozen cells from liquid nitrogen in a 37° C water-bath, transfer to a tube containing 10 ml of Thaw Medium 1 + Insulin (no Geneticin), spin the cells down, resuspend the cells in pre-warmed Thaw Medium 1 + Insulin (no Geneticin), and then transfer the resuspended cells to a T25 flask and culture in a CO₂ incubator at 37° C overnight. The next day, replace the medium with fresh Thaw Medium 1 + Insulin (no Geneticin), and continue growing culture in a CO₂ incubator at 37° C until the cells are ready to be split. At the first passage, switch to Growth Medium 1B + 10 μ g/ml of Insulin (includes Thaw Medium 1, Insulin, and Geneticin). Cells should be split before they reach complete confluence.

To passage the cells, rinse the cells with phosphate buffered saline (PBS), and detach the cells from the culture vessel with 0.25% Trypsin/EDTA. Add Growth Medium 1B + 10 μ g/ml of Insulin (Includes Thaw Medium 1, Insulin, and Geneticin) and transfer to a tube, spin down the cells, and then resuspend the cells and seed appropriate aliquots of the cell suspension into new culture vessels. Sub-cultivation ratio: 1:5 to 1:10 weekly.

To freeze down the cells, rinse cells with phosphate buffered saline (PBS), and detach the cells from the culture vessel with Trypsin/EDTA. Add Growth Medium 1B + 10 μg/ml of Insulin (Includes Thaw Medium 1, Insulin, and Geneticin) and transfer to a tube, spin the cells down, and then resuspend in freezing medium (10% DMSO + 90% FBS). Place at -80°C overnight and place in liquid nitrogen the next day. Alternatively, vials may be placed directly into the liquid nitrogen.

Functional Validation and Assay Performance

The following assays are designed for 96-well format. To perform the assay in different tissue culture formats, the cell number and reagent volume should be scaled appropriately.

Materials Required but Not Supplied for Cell Culture

- Thaw Medium 1 (BPS Bioscience #60187) + 10 μg/ml of insulin
- Growth Medium 1B (BPS Bioscience #79531) + 10 μg/ml of insulin
- Insulin Solution from Bovine Pancreas (Sigma-Aldrich #10516)

Materials Required but Not Supplied for Cellular Assay

- H₂O₂: activator of Hippo pathway (activate MST kinases)
- Insulin
- Assay Medium: Thaw Medium 1 (BPS Bioscience #60187) + 10 μg/ml of insulin
- Insulin Solution from Bovine Pancreas (Sigma-Aldrich #10516)



Tel: 1.858.202.1401 **Fax:** 1.858.481.8694

Email: info@bpsbioscience.com

- Okadaic acid (BPS bioscience #27047): activator of Hippo pathway (activate MST kinases). Prepare 10 mM stock in DMSO.
- 96-well tissue culture plate or 96-well tissue culture-treated white clear-bottom assay plate
- ONE-Step™ Luciferase Assay System (BPS Bioscience #60690)
- Luminometer

Mycoplasma testing

The cell line has been screened using the PCR-based VenorGeM Mycoplasma Detection kit (Sigma-Aldrich) to confirm the absence of Mycoplasma species.

Inhibition of TEAD reporter activity by activator of Hippo pathway in TEAD Reporter – MCF7 cells


- Harvest TEAD Reporter MCF7 cells from culture in growth medium and seed cells at a density of 35,000 cells per well into white clear-bottom 96-well microplate in 45 μl of assay medium.
- 2) Incubate cells at 37°C in a CO₂ incubator for overnight.
- 3) Dilute the activators (H_2O_2 or okadaic acid) stock in assay medium. Add 5 μ l of diluted activators to the wells. The final concentration of DMSO in assay medium is 0.1%.
- 4) Add 5 µl of assay medium with same concentration of DMSO without activator to control wells.
- 5) Add 50 μl of assay medium with DMSO to cell-free control wells (for determining background luminescence).
- 6) Set up each treatment in at least triplicate.
- 7) Incubate cells at 37°C in a CO₂ incubator for 5-6 hours.
- 8) Perform luciferase assay using the ONE-Step™ Luciferase Assay System following the protocol provided: Add 100 µl of ONE-Step™ Luciferase reagent per well and rock at room temperature for ~15 minutes. Measure luminescence using a luminometer. *Note: If using other luciferase reagents from other vendors follow the manufacturer's assay protocol.*
- 9) Data Analysis: Obtain the background-subtracted luminescence by subtracting the average background luminescence (cell-free control wells) from the luminescence reading of all wells.

Tel: 1.858.202.1401 Fax: 1.858.481.8694


Email: info@bpsbioscience.com

Figure 1. Response of TEAD Reporter – MCF7 cells to Hippo pathway activators.

1A. H_2O_2 and Okadaic Acid Blocked TEAD Reporter Activity. The results are shown as background-subtracted luminescence values.



1B. Okadaic Acid Inhibition Dose Response Curve. The results are shown as percentage of luminescence. The background-subtracted luminescence of cells in the absence of okadaic acid was set at 100%. The EC50 of okadaic acid is $\sim 0.13~\mu M$.



Tel: 1.858.202.1401 **Fax:** 1.858.481.8694

Email: info@bpsbioscience.com

1C. H2O2 Inhibition Dose Response Curve. The results are shown as percentage of luminescence. The background-subtracted luminescence of cells in the absence of H_2O_2 was set at 100%. The IC50 of H2O2 is ~ 7.5 mM.





Figure 2. Response of TEAD Reporter – MCF7 cells to Hippo pathway inactivators. TEAD Reporter – MCF7 cells were seeded at a density of 35,000 cells per well into a white clear-bottom 96-well microplate in 100 μ l of assay medium. Cells were then incubated at 37°C in a CO₂ incubator for overnight. The next day, the assay medium was removed and 100 μ l of **Thaw medium 1 without serum** was added to each well to serum starve the cells. Cells were then incubated at 37°C in a CO₂ incubator for overnight. The next day, 100 μ l of assay medium was added to wells in triplicate for the indicated times. Luciferase was measured using the ONE-StepTM Luciferase Assay System.

Activation of Hippo-TEAD Luciferase Reporter following Serum Stimulation





6042 Cornerstone Court West, Suite B San Diego, CA 92121 **Tel:** 1.858.202.1401

Fax: 1.858.481.8694
Email: info@bpsbioscience.com

References

- Lamar JM et al. (2012) The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. <u>Proc Natl Acad Sci U S A.</u> 109(37):E2441-50. doi: 10.1073/pnas.1212021109.
- 2. Hata Y *et al.* (2013) Okadaic Acid: a tool to study the hippo pathway. *Mar Drugs.* 11(3):896-902. doi: 10.3390/md11030896.
- Bao Y et al. (2011) A cell-based assay to screen stimulators of the Hippo pathway reveals the inhibitory effect of dobutamine on the YAP-dependent gene transcription. <u>J Biochem.</u> 150(2):199-208.

License Disclosure

Purchase of this cell line grants you with a 10-year license to use this cell line in your immediate laboratory, for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make the cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit use of this cell line in humans or for therapeutic or drug use. The license does not permit modification of the cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license and result in an immediate cease of sales and distribution of BPS products to your laboratory. BPS does not warrant the suitability of the cell line for any particular use, and does not accept any liability in connection with the handling or use of the cell line. Modifications of this cell line, transfer to another facility, or commercial use of the cells may require a separate license and additional fees; contact sales@bpsbioscience.com for details. Publications using this cell line should reference BPS Bioscience, Inc., San Diego.